Pyruvate

– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Not Regularly Transfused, PYRUKYND® Significantly Increased Hemoglobin Level, Decreased Hemolysis and Improved Patient-Reported Outcomes – – Following FDA Approval in February,…

– Additional Data Presented at ASH Support the Potential of Mitapivat to Improve Ineffective Erythropoiesis and Iron Overload and Stabilize Bone Mineral Density in PK Deficiency Patients – – Mitapivat Is Under Regulatory Review in the…

CAMBRIDGE, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today…

– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with PK Deficiency in the U.S. This Quarter and in the EU in Mid-2021 – – Agios to Host Investor Webcast Today at 7:30 a.m. ET – CAMBRIDGE,…